Dyne Therapeutics Inc (DYN) USD0.0001
Dyne Therapeutics Inc. is a biotechnology company focused on developing therapeutics for patients with genetically driven diseases. The Company’s FORCE platform therapeutics consists of an oligonucleotide payload that it designs to target the genetic basis of the disease. With its FORCE platform, the Company has the flexibility to deploy different types of oligonucleotide payloads with specific mechanisms of action that modify target functions. Using its FORCE platform, the Company is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a proprietary Fab, a clinically validated linker and an oligonucleotide payload that it attaches to its Fab using the linker. Its DM1 program is focused on the development of a potentially disease-modifying treatment for DM1.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.